NovaBay Pharmaceuticals’ NeutroPhase is Focus of Dr. John Crew’s Presentation at Advanced Wound Care Care Symposium

By April 24, 2014

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic anti-microbial products, today announced that Dr. John R. Crew, Medical Director of the Advanced Wound Care Center at Seton Medical Center in Daly City, California, will present at the Spring Symposium on Advanced Wound Care. Dr. Crew will explain to the doctors attending the meeting that NovaBay’s NeutroPhase® Advanced Wound Cleanser offers a significant advance in the treatment of flesh-eating infections.

“People have been dying and losing limbs from these infections,” said Dr. Crew. “But we now have a way of stopping it.”

In his presentation at the symposium, which takes place from April 23-27, 2014 in Orlando, Florida, Dr. Crew will describe how he successfully used NovaBay’s NeutroPhase as an adjunct therapy to irrigate the wounds of four patients with life-threatening necrotizing fasciitis (also known as flesh-eating infections), in conjunction with an irrigation technique involving Negative Pressure Wound Therapy (NPWT). All of the patients healed completely and none lost any limbs.

“To save more lives and limbs, I believe it’s vitally important to communicate this new approach to other doctors,” said Dr. Crew.

Dr. Crew has already written about one of these cases in a recent paper in the medical journal WOUNDS. The paper in the medical journal WOUNDS describes first successful procedure that removes toxins from wounds with less invasive debridement and avoids possible amputation. And in addition to the four patients whose cases Dr. Crew will describe at the Orlando meeting, a dozen more patients have been successfully treated with the combination of NeutroPhase and NPWT, a procedure identified as the “Crew-NovaBay Minimally Invasive Surgical Procedure For Necrotizing Fasciitis.”

In his presentation, Dr. Crew will also explain the mechanism by which NeutroPhase works. The advanced wound cleanser is a stable, pure form of hypochlorous acid, a natural, relatively short half-lived, substance produced by white blood cells as a first defense against microbial invaders. The key innovation behind the development of NeutroPhase is NovaBay’s proprietary manufacturing process which produces a stabilized pure form of hypochlorous acid solution which does not contain any bleach impurities, which are often present in Dakin and Dakin-like solutions. Extensive lab tests show that NeutroPhase not only kills bacteria in seconds, but lab studies have also confirmed NeutroPhase directly neutralizes the toxins that destroy tissue and render the immune system dysfunctional in flesh-eating infections.

“We believe that NeutroPhase should be part of a new standard of care for these deadly infections, and are working hard to help patients and save lives by spreading the word about the new approach that Dr. Crew has pioneered,” said Dr. Ron Najafi, Chairman and Chief Executive Officer of NovaBay.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals is a clinical-stage biopharmaceutical company focused on addressing the unmet therapeutic needs of the global market for topical and localized anti-infectives.

About NeutroPhase®
NeutroPhase® is a 510(k)-cleared wound cleanser and is intended for use under the supervision of healthcare professionals for cleansing and removal of foreign material, including: microorganisms and debris from wounds; cleaning minor cuts, minor burns, superficial abrasions, and minor irritations of the skin; as well as moistening absorbent wound dressings. It is also intended for moistening and debriding acute and chronic dermal lesions, such as: Stage I-IV pressure ulcers, stasis ulcers, leg ulcers, diabetic foot ulcers, post surgical wounds, first and second degree burns, as well as grafted and donor sites.

NeutroPhase is a 0.01% pure hypochlorous acid in saline (with no bleach impurities, which are often present in Dakin and Dakin-like solutions). In in vitro laboratory models, NeutroPhase has shown to be fast-acting against bacteria, biofilm and toxins. Statements regarding necrotizing fasciitis and flesh-eating bacteria have not been reviewed by the FDA. More information on NeutroPhase and how to purchase it at: www.neutrophase.com.

Forward-looking Statements
This release contains forward-looking statements and opinions, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the general use of antibiotics in the United States and NovaBay’s possible effect on that use. The words “expect,” “potential,” “believe” and “will” are intended to identify these forward-looking statements.  Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in development, clinical trial, regulatory approval, production and marketing of the company’s product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company’s intellectual property or trade secrets, the company’s ability to obtain additional financing as necessary and unanticipated research and development and other costs. Other risks relating to NovaBay and Aganocide compounds, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website

NovaBay Pharmaceuticals Contacts
Thomas J. Paulson  
Chief Financial Officer
510-899-8809
Contact Thomas Paulson

Ana Kapor
Director, Investor Relations and Corporate Communications
NovaBay Pharmaceuticals, Inc.
510-899-8889
Contact Ana Kapor

 

TOP